Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 14:9:895917.
doi: 10.3389/fcvm.2022.895917. eCollection 2022.

Development and Validation of a Personalized, Sex-Specific Prediction Algorithm of Severe Atheromatosis in Middle-Aged Asymptomatic Individuals: The ILERVAS Study

Affiliations

Development and Validation of a Personalized, Sex-Specific Prediction Algorithm of Severe Atheromatosis in Middle-Aged Asymptomatic Individuals: The ILERVAS Study

Marcelino Bermúdez-López et al. Front Cardiovasc Med. .

Abstract

Background: Although European guidelines recommend vascular ultrasound for the assessment of cardiovascular risk in low-to-moderate risk individuals, no algorithm properly identifies patients who could benefit from it. The aim of this study is to develop a sex-specific algorithm to identify those patients, especially women who are usually underdiagnosed.

Methods: Clinical, anthropometrical, and biochemical data were combined with a 12-territory vascular ultrasound to predict severe atheromatosis (SA: ≥ 3 territories with plaque). A Personalized Algorithm for Severe Atheromatosis Prediction (PASAP-ILERVAS) was obtained by machine learning. Models were trained in the ILERVAS cohort (n = 8,330; 51% women) and validated in the control subpopulation of the NEFRONA cohort (n = 559; 47% women). Performance was compared to the Systematic COronary Risk Evaluation (SCORE) model.

Results: The PASAP-ILERVAS is a sex-specific, easy-to-interpret predictive model that stratifies individuals according to their risk of SA in low, intermediate, or high risk. New clinical predictors beyond traditional factors were uncovered. In low- and high-risk (L&H-risk) men, the net reclassification index (NRI) was 0.044 (95% CI: 0.020-0.068), and the integrated discrimination index (IDI) was 0.038 (95% CI: 0.029-0.048) compared to the SCORE. In L&H-risk women, PASAP-ILERVAS showed a significant increase in the area under the curve (AUC, 0.074 (95% CI: 0.062-0.087), p-value: < 0.001), an NRI of 0.193 (95% CI: 0.162-0.224), and an IDI of 0.119 (95% CI: 0.109-0.129).

Conclusion: The PASAP-ILERVAS improves SA prediction, especially in women. Thus, it could reduce the number of unnecessary complementary explorations selecting patients for a further imaging study within the intermediate risk group, increasing cost-effectiveness and optimizing health resources.

Clinical trial registration: [www.ClinicalTrials.gov], identifier [NCT03228459].

Keywords: atherosclerosis; cardiovascular disease; cardiovascular risk assessment; machine learning; recursive partitioning classification trees; vascular ultrasound.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Analysis pipeline. ASCVD, atherosclerotic cardiovascular disease; OR, odds ratio; SD, standard deviation.
FIGURE 2
FIGURE 2
Personalized Algorithm for Severe Atheromatosis Prediction in men. The structure of the classification tree in men is represented. The probability of severe atheromatosis, which corresponds to the proportion of affected patients, is shown inside circles in the final nodes. The barplot offers a clearer visualization of this prevalence with its 95% confidence interval. The colors green, yellow, and red indicate the level of risk (low, intermediate, or high) identified after calibration. The units were as follows: age, year; GFR, ml/min/m2; SBP, mmHg; total cholesterol, mg/dl. GFR, glomerular filtration rate, SBP, systolic blood pressure.
FIGURE 3
FIGURE 3
Personalized Algorithm for Severe Atheromatosis Prediction in women. The probability of severe atheromatosis, which corresponds to the proportion of affected patients, was shown inside circles in the final nodes. The barplot offers a clearer visualization of this prevalence with its 95% confidence interval. The colors green, yellow, and red indicate the level of risk (low, intermediate, or high, respectively) identified after calibration. Hypertension and dyslipidemia refer to patients who had prior clinical diagnostic of hypertension or dyslipidemia in their clinical records. The units were as follows: Age: year; BMI: kg/m2; SBP, mmHg; total cholesterol: mg/dL; uric acid: mg/dl; waist perimeter: cm. BMI, body mass index; SBP, systolic blood pressure.
FIGURE 4
FIGURE 4
Clinical predictor importance in the PASAP-ILERVAS in both sexes. A variable importance score was calculated using the improvement measure attributable to each predictor in its role as splitter, plus the goodness for all splits in which it was a surrogate. The values of importance were scaled up to sum 100%. SBP, systolic blood pressure; BMI, body mass index; GFR, glomerular filtration rate.
FIGURE 5
FIGURE 5
Comparison of the PASAP-ILERVAS with the SCORE risk score. Barplots contain the main performance metrics of PASAP-ILERVAS and SCORE risk model in L&H-risk individuals: (A) specificity; (B) sensitivity; (C) accuracy; (D) positive predictive model; (E) ROC curve in men; (F) ROC curve in women. The ROC curves reflect the area under the curve between sensitivity and complementary of specificity with both models. SCORE, Systematic COronary risk Evaluation; ROC, Receiver Operating Characteristic.

Similar articles

Cited by

  • Health Equity in Clinical Research Informatics.
    Maurud S, Henni SH, Moen A. Maurud S, et al. Yearb Med Inform. 2023 Aug;32(1):138-145. doi: 10.1055/s-0043-1768720. Epub 2023 Jul 6. Yearb Med Inform. 2023. PMID: 37414033 Free PMC article. Review.

References

    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020) 41:111–88. - PubMed
    1. López-Melgar B, Fernández-Friera L, Oliva B, García-Ruiz JM, Peñalvo JL, Gómez-Talavera S, et al. Subclinical atherosclerosis burden by 3D ultrasound in mid-life: the PESA study. J Am Coll Cardiol. (2017) 70:301–13. 10.1016/j.jacc.2017.05.033 - DOI - PubMed
    1. Bermúdez-López M, Martínez-Alonso M, Castro-Boqué E, Betriu À, Cambray S, Farràs C, et al. Subclinical atheromatosis localization and burden in a low-to-moderate cardiovascular risk population: the ILERVAS study. Rev Esp Cardiol. (2020) 74:1042–53. 10.1016/j.rec.2020.09.015 - DOI - PubMed
    1. Marrugat J, Vila J, Baena-Diez JM, Grau M, Sala J, Ramos R, et al. [Relative validity of the 10-year cardiovascular risk estimate in a population cohort of the REGICOR study]. Rev Esp Cardiol. (2011) 64:385–94. 10.1016/j.rec.2010.12.017 - DOI - PubMed
    1. Gbd 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. (2020) 396:1204–22. - PMC - PubMed

Associated data